Elevated thrombin generation in patients with congenital disorder of glycosylation and combined coagulation factor deficiencies. (28th July 2019)

• Record Type: Journal Article
• Authors: Pascreau, Tiffany; de la Morena‐Barrio, Maria E.; Lasne, Dominique; Serrano, Mercedes; Bianchini, Elsa; Kossorotoff, Manoelle; Boddaert, Nathalie; Bruneel, Arnaud; Seta, Nathalie; Vicente, Vicente; de Lonlay, Pascale; Corral, Javier; Borgel, Delphine
• Is Part Of: Journal of thrombosis and haemostasis. Volume 17:Number 11(2019)
• Page Start: 1798
• Page End: 1807
• Publication Date: 2019-07-28
• Subjects: coagulation disorder -- congenital disorder of glycosylation -- thrombin generation assay; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.14559
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract: Background: Congenital disorders of glycosylation are rare inherited diseases affecting many different proteins. The lack of glycosylation notably affects the hemostatic system and leads to deficiencies of both procoagulant and anticoagulant factors. Objective: To assess the hemostatic balance in patients with multiple coagulation disorders by using a thrombin generation assay. Method: We performed conventional coagulation assays and a thrombin generation assay on samples from patients with congenital disorder of glycosylation. The thrombin generation assay was performed before and after activation of the protein C system by the addition of soluble thrombomodulin. Results: A total of 35 patients were included: 71% and 57% had low antithrombin and factor XI levels, respectively. Protein C and protein S levels were abnormally low in 29% and 26% of the patients, respectively, whereas only 11% displayed low factor IX levels. Under baseline conditions, the thrombin generation assay revealed a significantly higher endogenous thrombin potential and thrombin peak in patients, relative to controls. After spiking with thrombomodulin, we observed impaired involvement of the protein C system. Hence, 54% of patients displayed a hypercoagulant phenotype in vitro. All the patients with a history of stroke‐like episodes or thrombosis displayed this hypercoagulant phenotype. Conclusion: A thrombin generation assay revealed a hypercoagulant in vitro phenotype under baseline condition; this was accentuated by impaired involvement of the protein C system. This procoagulant phenotype may thus reflect the risk of severe vascular complications. Further research will have to determine whether the thrombin generation assay is predictive of vascular events.